Finance

Beta
Lists
GLUE:NASDAQ
Monte Rosa Therapeutics Inc
$16.37
-5.70%
(-0.99) 1D
$17.00
+3.85% (+0.63)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GLUE...
Open
$17.46
High
$17.80
Low
$16.25
Mkt. cap
1.38B
Avg. vol.
775.35K
Volume
950.29K
52-wk high
$25.77
52-wk low
$4.12
EPS
-$1.46
Beta
1.60
Shares outstanding
84.48M
No. of employees
187
Open
$17.46
High
$17.80
Low
$16.25
Mkt. cap
1.38B
Avg. vol.
775.35K
Volume
950.29K
52-wk high
$25.77
52-wk low
$4.12
EPS
-$1.46
Beta
1.60
Shares outstanding
84.48M
No. of employees
187
Analyst outlook
Analyst Ratings
Based on 7 analysts giving stock ratings to GLUE in the past 3 months
Strong Buy
Buy
7
Hold
0
Sell
0
12 month forecast
Based on 7 Wall Street analysts offering 12 month price targets for GLUE in the last 3 months.
Highest
Current $16.37
$37.00 (+126.02%)
Average
$32.80 (+100.37%)
Lowest
$29.00 (+77.15%)
News stories
From sources across the web
About Monte Rosa Therapeutics Inc
CEO-
Employees187
Founded2019
HeadquartersBoston, Massachusetts, United States
SectorBiotechnology
Websitemonterosatx.com
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$0.45 / -$0.38
-19.07%miss
Revenue / Est. (USD)
4.21M / 11.39M
-63.02%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
23.19M
12.77M
2.78M
4.21M
Cost of goods sold
29.04M
34.65M
39.89M
41.82M
Cost of revenue
29.04M
34.65M
39.89M
41.82M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9.70M
11.09M
12.60M
12.42M
Operating expense
9.70M
11.09M
12.60M
12.42M
Total operating expenses
38.75M
45.74M
52.50M
54.24M
Operating income
-15.55M
-32.98M
-49.72M
-50.03M
Other non operating income
-
-
-
-
EBT including unusual items
-11.10M
-30.26M
-46.08M
-44.45M
EBT excluding unusual items
-11.10M
-30.26M
-46.08M
-44.45M
Income tax expense
1.20M
-3.18M
59.00K
52.00K
Effective tax rate
-10.81%
10.50%
-0.13%
-0.12%
Other operating expenses
-
-
-
-
Net income
-12.30M
-27.08M
-46.14M
-44.50M
Net profit margin
-53.01%
-212.10%
-1,658.94%
-1,057.08%
Earnings per share
-0.15
-0.33
-0.55
-0.45
Interest and investment income
3.07M
2.75M
3.69M
5.59M
Interest expense
-
-
-
-
Net interest expenses
3.07M
2.75M
3.69M
5.59M
Depreciation and amortization charges
-
-
-
-
EBITDA
-13.43M
-30.88M
-47.63M
-48.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer